Milestone Pharmaceuticals Stock Performance
| MIST Stock | USD 1.85 0.01 0.54% |
On a scale of 0 to 100, Milestone Pharmaceuticals holds a performance score of 9. The company secures a Beta (Market Risk) of 1.66, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Milestone Pharmaceuticals will likely underperform. Please check Milestone Pharmaceuticals' maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Milestone Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Wills Robert James of 40000 shares of Milestone Pharmaceuticals at 1.45 subject to Rule 16b-3 | 08/28/2024 |
2 | Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors | 09/04/2024 |
3 | Disposition of 80000 shares by Saik Andrew of Milestone Pharmaceuticals at 1.585 subject to Rule 16b-3 | 09/06/2024 |
4 | TD Cowen holds Buy on Milestone Pharmaceuticals stock, expects peak sales of 441M - Investing.com India | 09/09/2024 |
5 | Acquisition by Truex Paul F of 22870 shares of Milestone Pharmaceuticals at 1.54 subject to Rule 16b-3 | 09/13/2024 |
6 | TRANSFORM YOUR SPACE WITH AIR WICKS NEWEST ESSENTIAL MIST DIFFUSER THE MODERN FRAGRANCE EXPERIENCE | 09/23/2024 |
7 | Individual investors account for 54 percent of Milestone Pharmaceuticals Inc.s ownership, while institutions account for 46 | 10/09/2024 |
8 | Milestone Pharmaceuticals files for mixed shelf offering | 11/12/2024 |
9 | After Golden Cross, Milestone Pharmaceuticals s Technical Outlook is Bright | 11/19/2024 |
| Begin Period Cash Flow | 7.6 M |
Milestone |
Milestone Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 150.00 in Milestone Pharmaceuticals on August 24, 2024 and sell it today you would earn a total of 35.00 from holding Milestone Pharmaceuticals or generate 23.33% return on investment over 90 days. Milestone Pharmaceuticals is currently generating 0.3757% in daily expected returns and assumes 2.9827% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Milestone, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Milestone Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Milestone Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Milestone Pharmaceuticals, and traders can use it to determine the average amount a Milestone Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1259
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MIST | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.98 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.38 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Milestone Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Milestone Pharmaceuticals by adding it to a well-diversified portfolio.
Milestone Pharmaceuticals Fundamentals Growth
Milestone Stock prices reflect investors' perceptions of the future prospects and financial health of Milestone Pharmaceuticals, and Milestone Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Milestone Stock performance.
| Return On Equity | -1.34 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 76.79 M | ||||
| Shares Outstanding | 53.33 M | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 4.13 X | ||||
| Price To Sales | 91.95 X | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 5 M | ||||
| EBITDA | (56.84 M) | ||||
| Net Income | (59.69 M) | ||||
| Cash And Equivalents | 86.24 M | ||||
| Cash Per Share | 2.87 X | ||||
| Total Debt | 51.77 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.26 X | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (46.42 M) | ||||
| Earnings Per Share | (0.80) X | ||||
| Market Capitalization | 99.19 M | ||||
| Total Asset | 75.23 M | ||||
| Retained Earnings | (326.03 M) | ||||
| Working Capital | 65.81 M | ||||
| Current Asset | 110.42 M | ||||
| Current Liabilities | 7.17 M | ||||
About Milestone Pharmaceuticals Performance
Assessing Milestone Pharmaceuticals' fundamental ratios provides investors with valuable insights into Milestone Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Milestone Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (226.53) | (237.85) | |
| Return On Tangible Assets | (0.79) | (0.83) | |
| Return On Capital Employed | (0.90) | (0.94) | |
| Return On Assets | (0.79) | (0.83) | |
| Return On Equity | (3.56) | (3.38) |
Things to note about Milestone Pharmaceuticals performance evaluation
Checking the ongoing alerts about Milestone Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Milestone Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Milestone Pharmaceuticals may become a speculative penny stock | |
| Milestone Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1000 K. Net Loss for the year was (59.69 M) with profit before overhead, payroll, taxes, and interest of 5 M. | |
| Milestone Pharmaceuticals currently holds about 86.24 M in cash with (46.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Milestone Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: After Golden Cross, Milestone Pharmaceuticals s Technical Outlook is Bright |
- Analyzing Milestone Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Milestone Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Milestone Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Milestone Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Milestone Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Milestone Pharmaceuticals' stock. These opinions can provide insight into Milestone Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.